18 Jun 2026

CRC Research Update — June 18, 2026

Creator: The CRC Digest
Published: 2026-06-18T14:39:19Z

Today's colorectal cancer research highlights

Was this forwarded to you? Read on the web or subscribe free

IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.

Signal Key

TRIAL DATA clinical trial results, efficacy data, survival endpoints TREATMENT new treatment options, regimen changes, combination therapies REGULATORY FDA/EMA approvals, guideline updates, NCCN/ESMO changes RESEARCH cancer biology, biomarker discoveries, resistance pathways SCREENING screening, colonoscopy guidelines, liquid biopsy, molecular profiling LIVING WITH CRC survivorship, quality of life, side effects, patient decision-making, caregiver support

CRC Research Update

Circulating tumor DNA detection after surgery predicts recurrence in stage II-III colorectal cancer
A pilot study of 47 patients with high-risk stage II and III colorectal adenocarcinoma sequenced tissue with Oncomine Comprehensive Plus assay and plasma (4 weeks post-surgery) with Avenio ctDNA Targeted Panel V2 assays, with ctDNA positivity defined according to different criteria for evaluation as a predictive biomarker. (Scientific Reports)
Machine learning identifies immunotherapy-responsive subtypes in microsatellite-stable metastatic colorectal cancer
Transcriptomics analysis of metastatic and primary tumor biopsies from MSS mCRC patients treated with botensilimab (Fc-enhanced anti-CTLA-4) ± balstilimab (anti-PD-1) used self-organizing map machine learning to stratify tumors into four molecular types, including a liver-like (LIV) subtype characterized by metabolic reprogramming and immunosuppressive signatures. (Oncogene)
POSTN+ fibroblasts form barriers that block immunotherapy in dMMR/MSI-H colorectal cancer
Analysis of 34 CRC patients treated with immune checkpoint blockade identified POSTN+ cancer-associated fibroblasts that were significantly enriched in non-responders and encapsulated tumors, forming barriers in the tumor microenvironment. (Cancer Letters)
Black men in Louisiana show low colorectal cancer screening awareness despite high risk
A statewide survey of Black men aged 30-44 in Louisiana found limited awareness of screening guidelines, low perceived risk, and structural barriers to care, highlighting the need for targeted interventions in a population experiencing the highest CRC incidence and mortality. (Ethnicity & Health)

🔬 Under 50 Spotlight

Research relevant to early-onset and younger CRC patients

Second primary cancers after early-onset CRC show distinct risk factors
A Chinese study of 13,302 CRC patients found 4.77% developed second primary cancers, with age-stratified analyses revealing heterogeneous risk factors—radiotherapy was the only independent factor in patients under 50. (Journal of Investigative Surgery)
Early-onset stage IV mucinous adenocarcinoma shows 18-month median survival
SEER analysis of 1,542 patients aged ≤50 with stage IV colorectal mucinous adenocarcinoma found median survival of 18 months and 5-year cancer-specific survival of 14.3%, with lung metastases significantly reducing survival. (Surgery)

🧬 Biomarker Spotlight

Research by genetic subtype — KRAS, BRAF, MSI-H, HER2, and more

KRAS G13D-mutant metastatic rectal cancer achieves 16.6 months disease control with TAS-102 plus bevacizumab
A 57-year-old man with KRAS G13D-mutant metastatic rectal cancer and fluoropyrimidine intolerance achieved approximately 16.6 months of disease control with trifluridine/tipiracil plus bevacizumab integrated with liver-directed treatments, substantially exceeding SUNLIGHT trial median PFS. (Anticancer Drugs)
Ultra-high TMB POLE-mutated stage II CRC patient develops severe renal toxicity after adjuvant immunotherapy
A 28-year-old with stage IIB POLE-mutated MSS CRC whose TMB reached 717 mutations/Mb developed severe renal toxicity after off-label adjuvant envafolimab, raising questions about the safety of ICIs in ultra-hypermutated early-stage disease. (AME Case Reports)

Research continues to reveal the molecular complexity of colorectal cancer and new paths toward more personalized treatment.

CRC Research Update

Subscribe to The CRC Digest